A Rosuvastatin Kedvezo Additiv Hatasa Thrombocytaaggregaios Paramerekre Cerebrovascularis Betegek Eseten

Translated title of the contribution: The positive additive effect of rosuvastatin on platelet aggregation parameters in patients with cerebrovascular disease

Research output: Contribution to journalArticle

Abstract

Statin therapy is the cornerstone of antiatherosclerotic treatment, and it considered obligatory in the secondary prevention of atherosclerotic diseases. Rosuvastatin is well-known and efficacious lipid-lowering agent and seems to have benefitial antiplatelet efficacy and anti-inflammatory profile. The aim of our study was to determined the antiplatelet effect of 20 mg rosuvastatin (Xeter, Richter Gedeon Nyrt.) in clopidogrel treated cerebrovascular patients. 20 patients with documented ischaemic cerebrovascular events and on 75 mg clopidogrel daily treatment were included in our study. 20 mg generic rosuvastatin significantly decreased total cholesterol (5.67 vs. 3.99 mmol/l, p

Original languageHungarian
Pages (from-to)517-521
Number of pages5
JournalLege Artis Medicinae
Volume25
Issue number11-12
Publication statusPublished - 2015

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this